David is an international thought-leader in healthcare risk management, with a particular interest in regenerative medicines. His multi-disciplinary research seeks to evaluate and develop systematic, rigorous and transparent risk management tools supporting the translation of life-science innovations into commercially viable products and services.
In all cases, David strives to conduct research that is both academically rigorous and commercially practicable. His expertise spans the ‘Valley of Death,’ encompassing regulation, engineering and finance.
At the SENS Research Foundation David leads all aspects of the Alliance Programs. He currently manages the CTSCC (CASMI Translational Stem Cell Consortium) program, the Alliance program and the development of a Rejuvenation Biotechnology Translational Consortium (RBTC). Within CTSCC, David leads all research activities pertaining to risk. David’s work can be found in a range of high impact journals including Nature, Nature Biotechnology, Nature Medicine and Cell Stem Cell. Additionally, David serves as an Editorial Board member for a range of international academic and industrial journals. David also produces a popular blog, Cell Therapy Industry 2027, with the Centre for the Commercialisation of Regenerative Medicine.
David is an active Fellow of the Royal Institution of Great Britain and the Royal Society for the Advancement of Arts and Manufacturing. David has successfully passed the Charted Analyst in Alternative Investments (CAIA) Level 1 examination. David indulges his entrepreneurial spirit through his consultancy, Translation Ventures Ltd, providing timely and pragmatic advice and training to a range of stakeholders in healthcare translation, including the venture capital community. Additionally, David is a strategic advisor to a number of SMEs pursuing excellence in healthcare risk management solutions, including Spoonful of Sugar and Oxford Risk.
David completed his undergraduate studies in Biochemical Engineering at University College London with First Class Honors and his Masters, investigating the commercialisation of regenerative therapies, jointly at the Harvard Stem Cell Institute and Harvard Business School (Prof. William Sahlman). David received a DPhil (PhD) in Musculoskeletal Sciences at the University of Oxford.